Cereno Scientific

5,81 SEK

+0,26 %

Mindre end 1K følgere

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

+0,26 %

-10,55 %

-16,95 %

-22,60 %

-36,14 %

+19,49 %

+217,91 %

+218,96 %

-3,43 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Markedsværdi

1,81 mia. SEK

Aktieomsætning

4,15 mio. SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

27.5

2026

Delårsrapport Q1'26

17.6

2026

Generalforsamling '26

26.8

2026

Delårsrapport Q2'26

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelsei går

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific

Selskabsmeddelelse27.2.2026, 06.45

Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025)

Cereno Scientific

Eksterne analyser20.2.2026, 10.31

Cereno Scientific: CMD reaffirms shifting focus to clinical delivery - Edison

Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by key opinion leader (KOL) and patient perspectives, ...

Cereno Scientific

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse4.2.2026, 09.00

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease

Cereno Scientific

Pressemeddelelse3.2.2026, 06.45

Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026

Cereno Scientific

Pressemeddelelse2.2.2026, 13.00

Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026

Cereno Scientific

Pressemeddelelse28.1.2026, 12.02

Cereno Scientific to Present CS014 Data and Participate in Panel at Scientific Conference PVRI 2026 Dublin

Cereno Scientific

Pressemeddelelse16.1.2026, 06.45

Cereno Scientific: Invitation to Capital Markets Day 2026

Cereno Scientific

Pressemeddelelse14.1.2026, 12.15

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases

Cereno Scientific

Eksterne analyser13.1.2026, 06.18

Cereno Scientific: Entering a value inflection phase - Edison

We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II development of CS014 shortly thereafter. With the FDA...

Cereno Scientific

Selskabsmeddelelse8.1.2026, 09.45

Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP

Cereno Scientific

Pressemeddelelse18.12.2025, 13.50

Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements

Cereno Scientific

Pressemeddelelse18.12.2025, 09.00

Cereno Scientific to Host Capital Markets Day on February 5, 2026

Cereno Scientific

Pressemeddelelse12.12.2025, 06.45

Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026

Cereno Scientific

Selskabsmeddelelse8.12.2025, 21.25

Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)

Cereno Scientific

Pressemeddelelse3.12.2025, 07.00

Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18

Cereno Scientific

Selskabsmeddelelse30.11.2025, 09.17

Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific

Pressemeddelelse28.11.2025, 18.31

Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium

Cereno Scientific

Selskabsmeddelelse28.11.2025, 18.30

Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific

Selskabsmeddelelse27.11.2025, 06.30

Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 - September 30, 2025)

Cereno Scientific

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.